2.Cancer incidence in five continents. Volume VII. IARC Sci Publ 1997;(143):i-xxxiv, 1-1240.
3.Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev 2014;15:9575-8.
5.Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-413.
6.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
7.Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
9.Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
10.Ries LA. Cancer statistics review 1973-1986. Maryland (MD): National Istitution of Health; 1989. p. III.1-VI.38.
12.Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975;15:617-31.
14.Global Cancer Observatory [Internet]. France: International Agency for Research on Cancer (IARC); c2022[cited 2023 Feb 18]. Available from:
https://gco.iarc.fr/.
21.Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63.
23.Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
26.Armstrong BK, Barry MJ, Frydenberg M, Gardiner RA, Haines I, Carter SM. PSA testing for men at average risk of prostate cancer. Public Health Res Pract 2017;27:2731721.
27.Prostate cancer [Internet]. Israel: The Israel Cancer Association; [cited 2023 Feb 18]. Available from:
https://en.cancer.org.il.
29.Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319:1901-13.
30.Fujisawa M. Prostate cancer screening recommendations/algorithms. In: Fujisawa M, editor. Screening guideline for prostate cancer 2018. Tokyo (Japan): The Japanese Urological Association; 2018. p. 6-8.
34.Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
35.Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75.
36.Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer 2007;110:1255-63.
37.Lin SS, Clarke CA, Prehn AW, Glaser SL, West DW, O'Malley CD. Survival differences among Asian subpopulations in the United States after prostate, colorectal, breast, and cervical carcinomas. Cancer 2002;94:1175-82.
39.Raymundo EM, Rice KR, Chen Y, Zhao J, Brassell SA. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. BJU Int 2011;107:1216-22.
40.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
42.Ngelangel CA, Wang EH. Cancer and the Philippine Cancer Control Program. Jpn J Clin Oncol 2002;32(Suppl):S52-61.
43.Takiar R, Krishnan SK, Shah VP. A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India-part II. Asian Pac J Cancer Prev 2014;15:5681-4.
46.Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018;6:e555-67.
47.Nemati S, Saeedi E, Lotfi F, Nahvijou A, Mohebbi E, Ravankhah Z, et al. National surveillance of cancer survival in Iran (IRANCANSURV): analysis of data of 15 cancer sites from nine population-based cancer registries. Int J Cancer 2022;151:2128-35.
48.Lei WK, Yu XQ, Lam C, Leong WK. Survival analysis of 2003-2005 data from the population-based Cancer Registry in Macao. Asian Pac J Cancer Prev 2010;11:1561-7.
49.Hung CF, Yang CK, Ou YC. Urologic cancer in Taiwan. Jpn J Clin Oncol 2016;46:605-9.
52.Ling A. Trends in incidence, mortality and survival of selected cancers, 1968-2020. In: Ling A, editor. Singapore Cancer Registry Annual Report 2020. Singpore: National Registry of Diseases Office; 2022. p. 38-49.